Main Article Content
Abstract
Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn’s disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions. Drugs such as proteins and peptides that are known to degrade in the extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. In order to achieve effective therapeutic outcomes, it is imperative that the designed delivery system specifically targets the drugs into the colon. The aim of the current research is to perform invitro release profile of eudragit loaded capecitabine alginate beads for targeted drug delivery system to provide a desired drug concentration in the body by delivering a therapeutic amount of drug to a target site. It is suitable and required for the drugs having instability, low solubility, and short half-life, a large volume of distribution, poor absorption, low specificity, and therapeutic index. Targeting may provide maximum therapeutic activity.